
    
      The purpose of this study is to evaluate the progression-free survival (PFS) in participants
      with metastatic colorectal cancer when treated with the monoclonal antibody IMC-1121B
      (ramucirumab) in combination with the modified FOLFOX-6 [folinic acid (FA) + fluorouracil
      (5-FU) + oxaliplatin, mFOLFOX-6] chemotherapy regimen as first-line therapy.
    
  